


CBSA NEWS IN REVIEW



A BRIEF OVERVIEW OF COLORADO'S MEDICAL DEVICE AND BIOPHARMA INDUSTRIES

18 April – 24 April

COMPANY SPOTLIGHT

- **GlobelImmune, Inc.** (Louisville) reported that use of GI-5005 in addition to standard of care (SOC) resulted in 94% early virologic response (EVR) in treatment naïve patients with hepatitis C in a Phase 2 clinical trial. EVR is defined as at least a 99% reduction in the virus load at the 12 week mark, and serves as early indicator of the likelihood of eradicating the virus or achieving sustained virologic response (SVR).
- **Array BioPharma Inc.** (Boulder) announced that ARRY-543 showed promising results in a phase I clinical trial. The drug showed positive results in approximately half the participants with ErbB2-positive metastatic breast cancer and other ErbB2-expressing cancers. ARRY-543 is now in Phase 1B clinical trials to test its effect when used in combination with various chemotherapeutics.
- **Baxa Corporation** (Englewood) celebrated Earth Day by announcing the launch of its 'ecological' program to encourage smart use of natural resources. Historically, Baxa has chosen product designs and raw materials that reduce waste and improve patient safety and minimize environmental impact. More recently, the company has introduced specific initiatives for reducing its environmental impact and advancing its environmental stewardship.
- **Pfizer** (Centennial) and the University College London announce collaboration to advance the development of stem cell-based therapies. The goal of the collaboration between pfizer regenerative medicine and UCL is the development of treatment for macular degeneration.

PEOPLE

- CBSA's annual all members meeting brought several new additions and changes to the organization's board:
 - Rick Jory, CEO of Sandhill Scientific, was named chairman of the board
 - Dr. Richard Duke, a founder of GlobelImmune, was named vice chairman
 - Other new members include: Joe Bagan, CEO and president, Sharklet Technologies; Chris Clement, senior director of contracts and business operations, Taligen Therapeutics; Dick Hinson, senior partner, Aurora Economic Development Council; Jim Kasic, director of clinical research, Otologics LLC; Carin Kutcipal, partner, Hogan and Hartson; Mark Lupa, partner, High Country Ventures; and Frank Ronchetti, CFO, BioDesix Inc., Broomfield.

SQUARE PEGS

- In recently released US News rankings of education programs, the University of Colorado Denver's medical school ranks fourth in the nation for its primary-care program and 29th for research.
- The \$500,000 Albany Medical Center Prize, the second largest scientific prize next to the Nobel, is being shared by Dr. Ralph Steinman of Rockefeller University, **Dr. Charles Dinarello, of**

the University of Colorado, and Dr. Bruce Beutler, of The Scripps Research Institute in La Jolla, Calif. for work that led to new treatments for rheumatoid arthritis and diabetes.

- Genetic Engineering News is organizing a conference on green biopharma for early December of this year. The meeting will take place in Philadelphia. We are in the early stages of recruiting for this conference. We're planning a high-end event, with academics and speakers from leading pharmaceutical and biotechnology companies. We would like to cover the following broad topics: 1) plant-, facility- and site-related conservation: waste minimization, recycling, water/electricity usage; 2) laboratory "greening" such as solvent substitution/minimization/recycling, air handling, electrical and water conservation, instrumentation; 3) process issues related to solvents, energy/water usage, "green" bioprocessing/chem-pharm processing (e.g., enzymes), process intensification. This is by no means a complete listing of acceptable topics; we are open to suggestions. If you are interested in speaking, please send an e-mail. Contact: Angelo DePalma, adp@tellurian.net.
- The Colorado BioScience Association's Education Committee is looking for companies that are interested in the externship program for this summer. They are interested in all companies, especially those involved in the sciences> For more information or to submit your company's name, please contact John Collar at 303-592-4072, or jcollar@cobioscience.com.

UPCOMING EVENTS

- The next BioBreakfast will occur on April 29 at 7:30 at the Anschutz Medical Campus and feature "Two Colorado Companies Making a Splash" highlighting Sharklet Technologies and BioAmps. More details and registration information are available [here](#).
- Apply Now: **The Rocky Mountain Life Science Investor Conference** is now accepting presenting company applications. Thirty of this region's most innovative private and public life science companies will present to a targeted audience of device, diagnostic and pharma investors. Increase your companies profile with a 20 minute presentation – apply at www.rmlic.com.

LEGISLATIVE UPDATE

- CBSA's lobbying team, have provided this week's legislative report.

Advance Colorado Center • 1625 Broadway Suite 950 • Denver Colorado 80202
Phone: 303-592-4073 • Fax: 303-592-4081 • www.CoBioScience.com